ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc

<< Previous

Bullboard Posts

Next >>

Post by Alex1726on Aug 18, 2021 12:56pm

126 Views

Post# 33723991

A massive rollback , No a huge one.

If i got it right , that $ is not even enough to start a phase I , another $30M to start and complete a phase I just befgore moving to nasdaq , that will be at least a 1 for 50 old shares and probably much more.

You can now appreciate how that management is incompetent , we will approach 500M SHARES and no phase I has started yet.

<< Previous

Bullboard Posts

Next >>

NervGen Pharma: Proof that NVG-291 works?